Approximately 70% of advanced breast cancers are hormone receptor-positive (HR+)/HER2-negative. Hormone therapies are widely used for the treatment of patients…
featured news
In recognition of multidisciplinary integrated cancer care, translational and clinical cancer research of excellence at the Vall d’Hebron University Hospital…
In an invited Viewpoint article recently published open access and ahead of print in the journal Molecular Oncology*, VHIO’s Joan…
Published in The Lancet Oncology results of the multicenter phase II MOUNTAINEER study (1) show that tucatinib plus trastuzumab had…
Advancing precision medicine in lung cancer, several studies (co) led by VHIO investigators have been presented, discussed, and debated at…
Pancreatic cancer accounts for almost as many deaths (466,000) as cases (496,000) because of its poor prognosis. It is the…
Led by Toni K. Choueiri at the Dana Farber Cancer Institute, Harvard Medical School in Boston (USA), the CONTACT-03 study…
New additional data from the phase 3 TALAPRO-2 study, presented today at the 2023 Annual Meeting of the American Society of…
Led by VHIO’s César Serrano, alongside first author Jonathan C. Trent at the Sylvester Comprehensive Cancer Center in Miami, an…
Presented today by VHIO’s Ana Oaknin at the 2023 ASCO Annual Meeting, 2-6 June (Chicago, IL), updated dose expansion data…
